---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-312030"
form_type: "8-K"
ticker: "KALV"
cik: "0001348911"
company_name: "KalVista Pharmaceuticals, Inc."
filed_at: "2022-12-27T23:59:59+00:00"
generated_at: "2026-06-20T22:47:33.875992+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# KalVista raises ~$58M in registered direct offering of 9.48M shares at $6.00/share plus warrants

## Summary
- 9,484,199 shares at $6.00 per share, plus pre-funded warrants for 182,470 shares at $5.999 each.
- Net proceeds expected ~$58M for clinical trials, commercial development, R&D, and working capital.
- Offering closes Dec 28, 2022; post-closing shares outstanding ~34.1M (dilution of ~9.7M shares).
- No underwriter; securities offered under existing shelf registration (File No. 333-256378).

## SEC filing metadata
- accession: 0001193125-22-312030
- form_type: 8-K
- ticker: KALV
- cik: 0001348911
- company_name: KalVista Pharmaceuticals, Inc.
- filed_at: 2022-12-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348911/000119312522312030/0001193125-22-312030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348911/000119312522312030/d420223d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-312030
- JSON: https://secwatch.observer/filing/0001193125-22-312030.json
- Plain text: https://secwatch.observer/filing/0001193125-22-312030.txt

## Key facts
- Material Agreements
  KalVista Pharmaceuticals, Inc. entered into Subscription Agreements with certain purchasers valued at approximately $58 million (effective 2022-12-23).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain purchasers
  - Value: approximately $58 million
  - Effective: 2022-12-23
  source text: On December 23, 2022, KalVista Pharmaceuticals, Inc. (the “Company”) entered into a subscription agreement (collectively, the “Subscription Agreements”) with certain purchasers, pursuant to which the Company agreed to issue and sell in a registered direct offering (the “Offering”) (i) an aggregate of 9,484,199 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (“Common Stock”) and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 182,470 shares of Common Stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1348911/000119312522312030/0001193125-22-312030-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.